v3.26.1
Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Cash equivalents $ 435 $ 417
Related party note receivable   5,179
Investment in MiNK Therapeutics, Inc. 22,927 24,277
Long-term investments 1,088 1,303
Total 24,450 31,176
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Cash equivalents 435 417
Related party note receivable   0
Investment in MiNK Therapeutics, Inc. 22,927 24,277
Long-term investments 1,088 1,303
Total 24,450 25,997
Significant Other Observable Inputs (Level 2) [Member]    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Cash equivalents 0 0
Related party note receivable   5,179
Investment in MiNK Therapeutics, Inc. 0 0
Long-term investments 0 0
Total 0 5,179
Significant Unobservable Inputs (Level 3) [Member]    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Cash equivalents 0 0
Related party note receivable   0
Investment in MiNK Therapeutics, Inc. 0  
Long-term investments 0  
Total $ 0 $ 0